Ponatinib for CML patients in routine clinical practice: the PONDEROSA study

Abstract Ponatinib, a third-generation tyrosine kinase inhibitor, is effective in patients with chronic myeloid leukemia (CML), particularly in cases of resistance or BCR::ABL1 T315I mutation. However, arterial occlusive events (AOEs) remain an important safety concern. The PONDEROSA registry evalua...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Thomas Schenk, Christian Fabisch, Thomas Ernst, Philipp Ernst, Susanne Saussele, Daniela Žáčková, Jiří Mayer, Hana Klamová, Andreas Hochhaus, for the German CML Study Group and the Czech Leukemia Study Group
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Springer 2026-01-01
Σειρά:	Annals of Hematology
Θέματα:	Chronic myeloid leukemia Ponatinib Registry Real-world evidence Dose optimization Arterial occlusive events
Διαθέσιμο Online:	https://doi.org/10.1007/s00277-026-06788-6
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!